Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 238

1.

Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.

Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE, Desprez PY, Kung HJ, deVere White RW.

Prostate. 2005 Dec 1;65(4):375-89.

PMID:
16037992
2.
3.
4.

Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.

Nesslinger NJ, Shi XB, deVere White RW.

Cancer Res. 2003 May 1;63(9):2228-33.

5.

p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.

Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ.

J Natl Cancer Inst. 1993 Oct 20;85(20):1657-69.

PMID:
7692074
6.

Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells.

Asirvatham AJ, Schmidt MA, Chaudhary J.

Prostate. 2006 Jun 15;66(9):921-35.

PMID:
16541417
7.

Molecular alterations associated with LNCaP cell progression to androgen independence.

Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack PC, Kung HJ, deVere White RW.

Prostate. 2004 Aug 1;60(3):257-71.

PMID:
15176055
8.
9.

Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis.

Downing S, Bumak C, Nixdorf S, Ow K, Russell P, Jackson P.

Mol Carcinog. 2003 Nov;38(3):130-40.

PMID:
14587098
10.

JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells.

Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, Wilding G.

Prostate. 2008 Jun 15;68(9):924-34. doi: 10.1002/pros.20737.

PMID:
18386285
11.

Expression of prostate specific antigen (PSA) is negatively regulated by p53.

Gurova KV, Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E, Gudkov AV.

Oncogene. 2002 Jan 3;21(1):153-7.

12.

Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.

Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, Belldegrun AS.

Prostate. 2003 Jun 1;55(4):299-307.

PMID:
12712409
13.

Analysis of differentially expressed genes in LNCaP prostate cancer progression model.

Xie BX, Zhang H, Wang J, Pang B, Wu RQ, Qian XL, Yu L, Li SH, Shi QG, Huang CF, Zhou JG.

J Androl. 2011 Mar-Apr;32(2):170-82. doi: 10.2164/jandrol.109.008748.

PMID:
20864652
14.

GREB1 is a novel androgen-regulated gene required for prostate cancer growth.

Rae JM, Johnson MD, Cordero KE, Scheys JO, Larios JM, Gottardis MM, Pienta KJ, Lippman ME.

Prostate. 2006 Jun 1;66(8):886-94.

PMID:
16496412
15.

The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7.

Vinall RL, Tepper CG, Shi XB, Xue LA, Gandour-Edwards R, de Vere White RW.

Oncogene. 2006 Mar 30;25(14):2082-93.

PMID:
16434975
16.

Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array.

Chetcuti A, Margan S, Mann S, Russell P, Handelsman D, Rogers J, Dong Q.

Prostate. 2001 May 1;47(2):132-40.

PMID:
11340636
17.

A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells.

Spurgers KB, Coombes KR, Meyn RE, Gold DL, Logothetis CJ, Johnson TJ, McDonnell TJ.

Oncogene. 2004 Mar 4;23(9):1712-23.

PMID:
14647426
18.

Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.

Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS.

Prostate. 2003 Apr 1;55(1):71-80.

PMID:
12640663
19.

Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer.

Carey JP, Asirvatham AJ, Galm O, Ghogomu TA, Chaudhary J.

BMC Cancer. 2009 Jun 7;9:173. doi: 10.1186/1471-2407-9-173.

20.

Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.

Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, Regan M, Libermann TA, Latham GJ, Sanda MG, Arredouani MS.

Prostate. 2008 Oct 1;68(14):1517-30. doi: 10.1002/pros.20803.

PMID:
18668517
Items per page

Supplemental Content

Support Center